Consensus statement for the treatment of infantile haemangiomas with propranolol
Australasian Journal of Dermatology2017Vol. 58(2), pp. 155–159
Citations Over TimeTop 10% of 2017 papers
Sarah Smithson, Marius Rademaker, Susan Adams, Stuart Bade, Philip Bekhor, Samantha Davidson, Amanda Dore, Catherine J. Drummond, Gayle Fischer, Alexander Gin, Claire Grills, Anne Halbert, Zerina Lokmic‐Tomkins, Emma McCahon, Vanessa Morgan, Dédée F. Murrell, David Orchard, Anthony Penington, Diana Purvis, John Relic, Susan J. Robertson, Aaron Robinson, Laura Scardamaglia, John Su, Swee T. Tan, Orli Wargon, Lachlan Warren, Li‐Chuen Wong, Tania Zappala, Roderic J. Phillips
Abstract
Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.
Related Papers
- → Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?(2019)6 cited
- → Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment(2018)8 cited
- → Update on Propranolol for Infantile Hemangioma: Where Are We Now?(2015)2 cited
- → Cost-utility analysis of propranolol versus corticosteroids in the treatment of proliferating infantile hemangioma in Italy(2015)3 cited
- → Variable response to propranolol therapy for infantile hemangiomas(2012)1 cited